section name header

General Information

Class Name(s):

Pronunciation:

Brand Name(s):

IMPORTANT WARNING:

Donanemab-azbt injection may cause a serious or life-threatening reaction called amyloid related imaging abnormalities (ARIA; a condition that may cause swelling and bleeding in the brain). If you experience any of the following symptoms, tell your doctor immediately or get emergency medical treatment: headache, confusion, dizziness, vision changes, nausea, difficulty walking or loss of balance, muscle weakness, difficulty speaking, or seizures.

Always carry identification stating that you are receiving donanemab-azbt injection. If you need an identification card, ask your pharmacist or doctor how to get one.

The chance that you will develop ARIA during your treatment with donanemab-azbt may be higher if you have a genetic (inherited) risk factor. Your doctor may order a blood test to help decide if this medication is right for you. Tell your doctor if you are taking medications that may cause bleeding.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests such as magnetic resonance imaging (MRI; a medical test that uses powerful magnets to take pictures of the inside of the body) scans before and during treatment to check your body's response to donanemab-azbt.

You will be given the Medication Guide. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit http://www.fda.gov/Drugs/DrugSafety/ucm085729.htmto obtain the Medication Guide.

Use

WHY is this medicine prescribed?

Donanemab-azbt injection is used to treat early Alzheimer's disease. Donanemab-azbt is in a class of medications called monoclonal antibodies. It works by reducing amyloid beta plaques, abnormal proteins that develop in the brain and contribute to the progression of Alzheimer's disease.

HOW should this medicine be used?

Donanemab-azbt comes as a solution (liquid) to be given intravenously (into the vein) by a doctor or a nurse at a hospital or clinic. It is given over 30 minutes every 4 weeks.

Your doctor will probably start you on a low dose of donanemab-azbt and gradually increase your dose.

Donanemab-azbt injection may cause serious reactions during or shortly after the infusion. A doctor or nurse will watch you carefully while you are receiving the medication. You may be given other medications to help prevent and treat reactions. If you experience any of the following symptoms, tell your doctor immediately: chills, sweating, nausea, vomiting, redness or irritation of the skin, headache, chest pain, or difficulty breathing or shortness of breath.

Your doctor may need to interrupt your treatment or stop your treatment depending on your response to the medication and any side effects that you experience. Be sure to tell your doctor how you are feeling during your treatment.

Donanemab-azbt controls Alzheimer's disease but does not cure it. Do not stop receiving donanemab-azbt without talking to your doctor.

Are there OTHER USES for this medication?

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Special

What SPECIAL PRECAUTIONS should I follow?

Before receiving donanemab-azbt injection,

What SPECIAL DIETARY instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

What should I do IF I FORGET to take a dose?

If you miss an appointment to receive donanemab-azbt injection, you should call your healthcare provider as soon as possible.

Side Effects

What SIDE EFFECTS can this medicine cause?

Donanemab-azbt injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING or HOW sections, call your doctor immediately or get emergency medical treatment:

Donanemab-azbt may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Miscellaneous

What OTHER INFORMATION should I know?

Keep a written list of all of the prescription and nonprescription (over-the-counter) medicines, vitamins, minerals, and dietary supplements you are taking. Bring this list with you each time you visit a doctor or if you are admitted to the hospital. You should carry the list with you in case of emergencies.

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. represents that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS® Patient Medication Information Copyright, 2025. The American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.

Selected Revisions: October 15, 2025.